LYR-210 + Sham procedure control
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Sinusitis
Conditions
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Trial Timeline
May 13, 2022 โ Apr 2, 2025
NCT ID
NCT05295459About LYR-210 + Sham procedure control
LYR-210 + Sham procedure control is a phase 3 stage product being developed by Lyra Therapeutics for Chronic Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05295459. Target conditions include Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis).
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05295459 | Phase 3 | Completed |
| NCT05219968 | Phase 3 | Completed |
Competing Products
20 competing products in Chronic Sinusitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |